Arun Nagaraj, MD
Neurology · Dallas, TXNPI 1861786576
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.5% of the total across 346 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 44 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations.
Across 346 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Sunovion Pharmaceuticals Inc.$631
- Novartis$548
- Biogen$472
- Bristol Myers Squibb$368
- Genentech USA, Inc.$354
- plus $3K from 38 others
Across 31 payments — averaging $7133.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$159K
- Genentech, Inc.$33K
- TG Therapeutics, Inc.$22K
- EMD Serono, Inc.$7K
Across 6 payments — averaging $74,629 each. An ownership or investment interest held by the physician or an immediate family member.
- Neurology Practice Consortium GPO, LLC$448K
What the payments were for
- Consulting fees$3004%
- Speaking & faculty fees$1342%
- Food & beverage$6,15292%
- Education$1342%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYSABRI$300
- Senza Spinal Cord Stimulation System$153
- BRIUMVI$125
- AUBAGIO$120
How this compares
$6,720 in reported general payments places this provider in the 65th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OnpattroPatisiran Sodium,lipid Complex | 18 | $605,321 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $306,710 |
| Kesimpta PenOfatumumab | 23 | $277,574 |
| CopaxoneGlatiramer Acetate | 20 | $153,036 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 18 | $145,404 |
| Avonex (4 Pack)Interferon Beta-1a | 14 | $132,024 |
| NuplazidPimavanserin Tartrate | 17 | $115,558 |
| Glatiramer Acetate | 18 | $23,139 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $20,076 |
| Dalfampridine ErDalfampridine | 38 | $19,067 |
| BriviactBrivaracetam | 12 | $16,259 |
| Emgality PenGalcanezumab-Gnlm | 18 | $12,967 |
| Dimethyl Fumarate | 18 | $3,303 |
| Teriflunomide | 23 | $3,250 |
| Gabapentin | 126 | $2,660 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alnylam Pharmaceuticals Inc.Onpattro | $37 | $605,32118 claims |
| CSL BehringPrivigen | $14 | $306,71013 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $247 | $153,03620 claims |
| BiogenAvonex (4 Pack) | $472 | $132,02414 claims |
| Acadia Pharmaceuticals IncNuplazid | $46 | $115,55817 claims |
| UCB, Inc.Briviact | $253 | $16,25912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,246 neurology providers in Texas.
Other neurology in Dallas
- Nirav PavasiaDallas$1.4M
- Benjamin GreenbergDallas$773K
- Waleed El-FekyDallas$587K
- Adnan SubeiDallas$477K
- Steven HerzogDallas$461K
- Priyanka ChaudhryDallas$329K
- Deborah FriedmanDallas$284K
- Mark AlbertsDallas$212K
- Aanchal TanejaDallas$169K
- Salman BhaiDallas$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.